1
|
Kim J, Baek S, Nam J, Park J, Kim K, Kang J, Yeom G. Simultaneous Detection of Infectious Diseases Using Aptamer-Conjugated Gold Nanoparticles in the Lateral Flow Immunoassay-Based Signal Amplification Platform. Anal Chem 2024; 96:1725-1732. [PMID: 38240676 DOI: 10.1021/acs.analchem.3c04870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2024]
Abstract
Various platforms for the accurate diagnosis of infectious diseases have been studied because of the emergence of coronavirus disease (COVID-19) in 2019. Recently, it has become difficult to distinguish viruses with similar symptoms due to the continuous mutation of viruses, and there is an increasing need for a diagnostic method to detect them simultaneously. Therefore, we developed a paper-based rapid antigen diagnostic test using DNA aptamers for the simultaneous detection of influenza A, influenza B, and COVID-19. Aptamers specific for each target viral antigen were selected and attached to AuNPs for application in a rapid antigen diagnosis kit using our company's heterogeneous sandwich-type aptamer screening method (H-SELEX). We confirmed that the three viruses could be detected on the same membrane without cross-reactivity based on the high stability, specificity, and binding affinity of the selected aptamers. Further, the limit of detection was 2.89 pg·mL-1 when applied to develop signal amplification technology; each virus antigen was detected successfully in diluted nasopharyngeal samples. We believe that the developed simultaneous diagnostic kit, based on such high accuracy, can distinguish various infectious diseases, thereby increasing the therapeutic effect and contributing to the clinical field.
Collapse
Affiliation(s)
- Jinwoo Kim
- SB BIOSCIENCE Inc., Room 120, Venture Building, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Sowon Baek
- SB BIOSCIENCE Inc., Room 120, Venture Building, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Jungmin Nam
- SB BIOSCIENCE Inc., Room 120, Venture Building, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Jeongeun Park
- SB BIOSCIENCE Inc., Room 120, Venture Building, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Kihyeun Kim
- Advanced Photonics Research Institute (APRI), Gwangju Institute of Science and Technology (GIST), 123 Cheomdan-gwagiro, Buk-gu, Gwangju 61005, Republic of Korea
| | - Juyoung Kang
- SB BIOSCIENCE Inc., Room 120, Venture Building, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Gyuho Yeom
- SB BIOSCIENCE Inc., Room 120, Venture Building, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| |
Collapse
|
2
|
Takahashi H, Nagamatsu H, Yamada Y, Toba N, Toyama-Kousaka M, Ota S, Morikawa M, Shinoda M, Takano S, Fukasawa S, Park K, Yano T, Mineshita M, Shinkai M. Surveillance of seasonal influenza viruses during the COVID-19 pandemic in Tokyo, Japan, 2018-2023, a single-center study. Influenza Other Respir Viruses 2024; 18:e13248. [PMID: 38188373 PMCID: PMC10767599 DOI: 10.1111/irv.13248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2023] [Revised: 12/13/2023] [Accepted: 12/13/2023] [Indexed: 01/09/2024] Open
Abstract
Introduction COVID-19 pandemic led to significant reductions in influenza detection worldwide, fueling debates on whether influenza truly ceased circulating in communities. The number of influenza cases decreased significantly in Japan, raising concerns about the potential risk of decreased immunity to influenza in the population. Our single-center study aimed to investigate influenza trends before and during the COVID-19 pandemic in Tokyo, Japan. Materials and Methods This cross-sectional study included patients of all ages who visited Tokyo Shinagawa Hospital between April 1, 2018, and March 31, 2023. Influenza and COVID-19 tests were conducted using Quick Navi-Flu2 and polymerase chain reaction (PCR). We analyzed data from before and during the COVID-19 epidemic, based on patient background, hospitalization, and deaths, collected from medical records. Results A total of 12 577 influenza tests were conducted, with approximately 100 tests consistently performed each month even in the influenza off-season. Throughout the observation period, 962 positive cases were identified. However, no cases were observed for 27 months between March 2020 and November 2022. Influenza A cases were reobserved in December 2022, followed by influenza B cases in March 2023, similar to the influenza incidence reports from Tokyo. The positivity rate during the 2022-2023 winter season was lower than before the COVID-19 epidemic and decreased in elderly patients, with no hospitalizations or deaths observed. Conclusion This single-center study provided actual trend data for influenza patients before and during COVID-19 outbreaks in Tokyo, which could offer insights into the potential impact and likelihood of influenza virus infection in Japan.
Collapse
Affiliation(s)
- Hidenori Takahashi
- Department of Respiratory Medicine Tokyo Shinagawa Hospital Tokyo Japan
- Department of Infection Control Tokyo Shinagawa Hospital Tokyo Japan
- Department of Respiratory Medicine St. Marianna University School of Medicine Kawasaki Japan
| | - Hiroki Nagamatsu
- Department of Respiratory Medicine Tokyo Shinagawa Hospital Tokyo Japan
| | - Yuka Yamada
- Department of Respiratory Medicine Tokyo Shinagawa Hospital Tokyo Japan
| | - Naoya Toba
- Department of Respiratory Medicine Tokyo Shinagawa Hospital Tokyo Japan
| | | | - Shinichiro Ota
- Department of Respiratory Medicine Tokyo Shinagawa Hospital Tokyo Japan
| | - Miwa Morikawa
- Department of Respiratory Medicine Tokyo Shinagawa Hospital Tokyo Japan
| | - Masahiro Shinoda
- Department of Respiratory Medicine Tokyo Shinagawa Hospital Tokyo Japan
| | - Syunsuke Takano
- Department of Infection Control Tokyo Shinagawa Hospital Tokyo Japan
| | - Suzuko Fukasawa
- Department of Infection Control Tokyo Shinagawa Hospital Tokyo Japan
| | - Kaeyoung Park
- Department of Infection Control Tokyo Shinagawa Hospital Tokyo Japan
| | - Takahiko Yano
- Department of Infection Control Tokyo Shinagawa Hospital Tokyo Japan
| | - Masamichi Mineshita
- Department of Respiratory Medicine St. Marianna University School of Medicine Kawasaki Japan
| | - Masaharu Shinkai
- Department of Respiratory Medicine Tokyo Shinagawa Hospital Tokyo Japan
| |
Collapse
|
3
|
Maamar A, Liard C, Doucet W, Reizine F, Painvin B, Delamaire F, Coirier V, Quelven Q, Guillot P, Lesouhaitier M, Tadié JM, Gacouin A. Acquired agitation in acute respiratory distress syndrome with COVID-19 compared to influenza patients: a propensity score matching observational study. Virol J 2022; 19:145. [PMID: 36085163 PMCID: PMC9463051 DOI: 10.1186/s12985-022-01868-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 08/16/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND A growing body of evidence reports that agitation and encephalopathy are frequent in critically ill Covid-19 patients. We aimed to assess agitation's incidence and risk factors in critically ill ARDS patients with Covid-19. For that purpose, we compared SARS-CoV-2 acute respiratory distress syndrome (ARDS) patients with a population of influenza ARDS patients, given that the influenza virus is also known for its neurotropism and ability to induce encephalopathy. METHODS We included all the patients with laboratory-confirmed Covid-19 infection and ARDS admitted to our medical intensive care unit (ICU) between March 10th, 2020 and April 16th, 2021, and all the patients with laboratory-confirmed influenza infection and ARDS admitted to our ICU between April 10th, 2006 and February 8th, 2020. Clinical and biological data were prospectively collected and retrospectively analyzed. We also recorded previously known factors associated with agitation (ICU length of stay, length of invasive ventilation, SOFA score and SAPS II at admission, sedative and opioids consumption, time to defecation). Agitation was defined as a day with Richmond Agitation Sedation Scale greater than 0 after exclusion of other causes of delirium and pain. We compared the prevalence of agitation among Covid-19 patients during their ICU stay and in those with influenza patients. RESULTS We included 241 patients (median age 62 years [53-70], 158 males (65.5%)), including 146 patients with Covid-19 and 95 patients with Influenza. One hundred eleven (46.1%) patients had agitation during their ICU stay. Patients with Covid-19 had significantly more agitation than patients with influenza (respectively 80 patients (54.8%) and 31 patients (32.6%), p < 0.01). After matching with a propensity score, Covid-19 patients remained more agitated than influenza patients (49 (51.6% vs 32 (33.7%), p = 0.006). Agitation remained independently associated with mortality after adjustment for other factors (HR = 1.85, 95% CI 1.37-2.49, p < 0.001). CONCLUSION Agitation in ARDS Covid-19 patients was more frequent than in ARDS influenza patients and was not associated with common risk factors, such as severity of illness or sedation. Systemic hyperinflammation might be responsible for these neurological manifestations, but there is no specific management to our knowledge.
Collapse
Affiliation(s)
- Adel Maamar
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France.
| | - Clémence Liard
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Willelm Doucet
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Florian Reizine
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Benoit Painvin
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Flora Delamaire
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Valentin Coirier
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Quentin Quelven
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Pauline Guillot
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Mathieu Lesouhaitier
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France
| | - Jean Marc Tadié
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France.,Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France
| | - Arnaud Gacouin
- CHU Rennes, Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Université de Rennes 1, 2, rue Henri Le Guilloux, 35033, Rennes Cedex 9, France.,Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France
| |
Collapse
|
4
|
Li T, Asakawa T, Liu H, Chu C, Lu H. The role of influenza in the era of COVID-19: Can we forget it? Biosci Trends 2022; 16:374-376. [PMID: 35850992 DOI: 10.5582/bst.2022.01297] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
COVID-19 has been a topic of interest since a pandemic struck in 2019. The morbidity of influenza tended to decrease due to the measures to prevent COVID-19. Indeed, influenza seems to be "ignored" in this era of COVID-19. However, influenza has not disappeared from the scene. Presented here are two examples of recent influenza epidemics in China and Australia. Possible interactions between COVID-19 and influenza are discussed. Measures against COVID-19 may reduce contact with influenza, subsequently reducing adaptive immunity against influenza in the general population. Influenza might not be center stage right now, but insufficient adaptive immunity in the population may potentially trigger a future influenza pandemic. Coinfection with COVID-19 and influenza might potentially be a thorny problem. Hence, influenza cannot be ignored. Governments around the world should take measures to prepare for a possible influenza pandemic in the future.
Collapse
Affiliation(s)
- Ting Li
- Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, China.,Centre of Environment and Population Health, School of Medicine and Dentistry, Griffith University, Brisbane, Australia
| | - Tetsuya Asakawa
- Institute of Neurology, the Third People's Hospital of Shenzhen, Shenzhen, China
| | - Hui Liu
- Medical Administration Department, Shenzhen Municipal Health Commission, Shenzhen, China
| | - Cordia Chu
- Centre of Environment and Population Health, School of Medicine and Dentistry, Griffith University, Brisbane, Australia
| | - Hongzhou Lu
- Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, China
| |
Collapse
|
5
|
Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, Hardwick HE, Visser LG, Openshaw PJM, Groeneveld GH, Semple MG, Baillie JK. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet 2022; 399:1463-1464. [PMID: 35344735 PMCID: PMC8956294 DOI: 10.1016/s0140-6736(22)00383-x] [Citation(s) in RCA: 164] [Impact Index Per Article: 82.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 02/18/2022] [Accepted: 02/22/2022] [Indexed: 12/24/2022]
Affiliation(s)
- Maaike C Swets
- Roslin Institute, University of Edinburgh, Edinburgh EH25 9RG, UK; Department of Infectious Diseases, Leiden University Medical Centre, Leiden University, Leiden, Netherlands
| | - Clark D Russell
- Centre for Inflammation Research, University of Edinburgh, Edinburgh EH25 9RG, UK
| | - Ewen M Harrison
- Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh EH25 9RG, UK
| | - Annemarie B Docherty
- Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh EH25 9RG, UK
| | - Nazir Lone
- Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh EH25 9RG, UK
| | - Michelle Girvan
- Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK
| | - Hayley E Hardwick
- Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
| | - Leonardus G Visser
- Department of Infectious Diseases, Leiden University Medical Centre, Leiden University, Leiden, Netherlands
| | | | - Geert H Groeneveld
- Department of Infectious Diseases, Leiden University Medical Centre, Leiden University, Leiden, Netherlands
| | - Malcolm G Semple
- Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Department of Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK
| | | |
Collapse
|